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Abstract
Background: Hypoparathyroidism in children is a heterogeneous group with diverse genetic etiologies. To aid
clinicians in the investigation and management of children with hypoparathyroidism, we describe the phenotype of
a 6-year-old child with hypoparathyroidism and short stature diagnosed with Kenny-Caffey syndrome (KCS) Type 2
and the subsequent response to growth hormone (GH) treatment.
Case presentation: The proband presented in the neonatal period with hypocalcemic seizures secondary to
hypoparathyroidism. Her phenotype included small hands and feet, hypoplastic and dystrophic nails, hypoplastic
mid-face and macrocrania. Postnatal growth was delayed but neurodevelopment was normal. A skeletal survey at
2 years of age was suggestive of KCS Type 2 and genetic testing revealed a novel de novo heterozygous mutation
c.1622C > A (p.Ser541Tyr) in FAM111A. At 3 years and 2 months, her height was 80cms (SDS −3.86). She had normal
overnight GH levels. GH therapy was commenced at a dose of 4.9 mg/m2/week for her short stature and low
height velocity of 5cms/year. At the end of the first and second years of GH treatment, height velocity was 6.5cms/
year and 7.2cms/year, respectively with maximal dose of 7.24 mg/m2/week.
Conclusion: This case highlights the phenotype and the limited response to GH in a child with genetically proven
KCS type 2. Long-term registries monitoring growth outcomes following GH therapy in patients with rare genetic
conditions may help guide clinical decisions regarding the use and doses of GH in these conditions.
Keywords: Kenny-Caffey syndrome Type 2, FAM111A gene, Growth hormone, Hypoparathyroidism, Short stature,
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Background
Hypoparathyroidism is an important cause of neonatal
hypocalcemia presenting in the first week of life [1]. It
is characterized by low or normal parathyroid hormone
(PTH) levels in the presence of hypocalcemia and
hyperphosphatemia. Although commonly seen as an
iatrogenic complication following anterior neck surgery
in adults, the etiology of hypoparathyroidism in chil-
dren is more diverse and includes a heterogeneous
group of disorders, many of which have a genetic basis
[2, 3]. An increased understanding of the genetic
etiology and improved genetic testing has provided an
opportunity to expand the molecular diagnosis of hypo-
parathyroidism [2].
Kenny-Caffey syndrome (KCS) is an uncommon cause
of hypoparathyroidism with one out of 37 patients re-
ported with this condition in a cohort of children with
primary hypoparathyroidism [3]. It is characterized by
proportionate short stature along with cortical thicken-
ing and medullary stenosis of tubular bones, delayed
closure of anterior fontanelle, eye abnormalities, and
hypoparathyroidism. The autosomal dominant form or
KCS Type 2 (OMIM 127000) caused by mutations in
FAM111A [4] is distinguished from the autosomal reces-
sive form (KCS Type 1), caused by mutations in tubulin-
folding cofactor E (TBCE) gene, by the absence of
* Correspondence: Catherine.Choong@health.wa.gov.au
1Department of Endocrinology, Princess Margaret Hospital, Perth, Australia
2School of Paediatrics and Child Health, The University of Western Australia,
Perth, Australia
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Abraham et al. International Journal of Pediatric Endocrinology  (2017) 2017:1 
DOI 10.1186/s13633-016-0041-7
microcephaly and mental retardation [5]. Awareness of
the different phenotypes and the underlying genetic mu-
tation improves the ability of the physician to undertake
appropriate investigations, predict patient outcomes and
provide appropriate genetic counselling [3]. We present
the clinical characteristics of a 6-year-old girl with neo-
natal hypocalcemia, post-natal short stature, macrocra-
nia and normal intellect diagnosed with KCS Type 2.
Case presentation
The proband was born by natural conception to non-
consanguineous Italian parents at 39 weeks of gestation
by an elective caesarean section for breech delivery with
a birth weight of 3.26kgs (SDS 0.1), length of 49cms
(SDS −0.1) and head circumference of 36cms (SDS 1.8).
She presented on day 8 of life with hypocalcemic sei-
zures secondary to hypoparathyroidism (Table 1) with
normal blood glucose and renal function. Normocalce-
mia was achieved with parenteral calcium gluconate in-
fusion. Thereafter, supplementation with oral elemental
calcium and calcitriol maintained appropriate serum
levels of calcium and phosphate. Her phenotype in-
cluded macrocrania and large persistent fontanelles. She
had relatively elfin facies with hypoplasia of the mid-
face, telecanthus, small palpebral fissures, a small
pinched upturned nose and a small chin (Fig. 1a and b).
Proportionate limb shortening with additional circum-
ferential skin folds was present. Hands and feet were
small with bilateral single palmar creases and triangular,
hypoplastic and dystrophic nails (Fig. 2). An ophthalmo-
logical examination in the neonatal period did not reveal
any abnormalities.
Her neurodevelopment was normal. However, linear
growth was poor (Fig. 1c) and dentition delayed; her first
tooth erupted at 16 months. At 1 year of age, her length
was 65.5cms (SDS −3.5) Figs. 3 and 4 demonstrate the
height and head circumference respectively. Macrocrania
was more pronounced during infancy and plateaued
after 2 years of age although the head circumference
continued to be disproportionate to the height. There
was no family history of short stature, macrocephaly,
skeletal and nail deformities or hypoparathyroidism. Par-
ents were clinically unaffected with maternal height of
162.5cms and paternal height of 182.9cms, the predicted
mid-parental target height was 166.2cms (SDS 0.4). Fig-
ure 5 demonstrates the overnight growth hormone (GH)
study [6] performed at 2.6 years of age. It showed a nor-
mal GH reserve with a peak of 15 μg/L with serum
insulin-like growth factor 1 (IGF-1) of 57 μg/L (SDS
−1.9). GH was measured using a solid-phase, two-site
chemiluminescent immunoassay on the Immulite 2000
XPi (Siemens Healthcare Diagnostics Inc, Deerfield, IL).
IGF-1 was measured by chemiluminescent immunoassay
on the automated analyser Diasorin Liaison (Diasorin
Inc, Stillwater, MN). At 3 years and 2 months, her height
was 80cms (SDS −3.86) (<3rd percentile on WHO
growth chart, <1st percentile on CDC growth chart) with
a height velocity of 5cms/year. GH treatment was com-
menced at 3 years and 3 months with a starting dose of
4.9 mg/m2/week (0.2 mg/kg/week) [7], under the
Pharmaceutical Benefits Scheme Growth Hormone Pro-
gram for ‘Short stature and slow growth’ [8]. This cat-
egory utilises the following auxological parameters on
the CDC growth charts; height <1st percentile on the
CDC growth chart and low height velocity (<3rd percent-
ile CDC growth chart). There were no side effects and
good compliance with administration of injections was
maintained.
Investigations: Initial investigations included a normal
echocardiogram, renal ultrasound and MRI brain.
There was also a persistent normocytic anaemia with
haemoglobin of 95gm/L (NR: 110–145) with normal
iron stores and haemoglobin electrophoresis. Karyotype
and FISH for 22q11.2 deletion were normal. There was
no pathogenic variant demonstrated on CASR, PTH
and GCMB gene analysis. Chromosomal microarray
revealed a small paternally inherited micro-duplication
of chromosome 17p13.2 not known to cause any of the
described phenotypic features. The proband’s father is
asymptomatic, not dysmorphic and has normal calcium
and PTH levels. A skeletal survey performed in the
neonatal period was inconclusive; however, the repeat
survey at 2 years of age was suggestive of KCS with
overtubulated long bones, metacarpals and metatarsals
with very little medullary space as shown in Fig. 6. The
anterior fontanelle was widely patent with multiple
Wormian bones. Further genetic testing revealed a
novel de novo heterozygous mutation c.1622C > A
(p. Ser541Tyr) in FAM111A. This genetic variant was
predicted to be probably damaging by PolyPhen (score
0.99) [9], deleterious by SIFT (score 0.0) [10] and
damaging by FATHMM (score −3.50) [11] suggesting
that the mutation may be damaging. Furthermore, this
variant is not present in the ExAC [12], 1000 Genomes
Table 1 Laboratory investigations with neonatal hypocalcaemia
Investigations Patient values Normal values
Serum calcium 1.15 2.15–2.75 mmol/l
Ionised calcium 0.72 1.1–1.4 mmol/l
Serum phosphate 4.07 1.4–2.6 mmol/l
Serum magnesium 0.47 0.7–1.1 mmol/l
Albumin 37 25–40gm/L
PTH <0.3 0.7–7pmol/l
Alkaline phosphatase 251 100–420U/l
Vitamin D 98 >50 nmol/l
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Project [13], and NHLBI GO Exome Sequencing
Project databases [14], supporting the putative
dominant effect of this mutation. The variant lies in the
peptidase domain of FAM111A, where a pathogenic
variant for KCS type 2 was previously identified [4, 15]
as shown in Fig. 7.
Follow-up: Hypoparathyroidism was treated with oral
calcium and calcitriol supplementation. Apart from
early echogenic changes in the renal pelvis at 2 years of
age, there has been no evidence of nephrocalcinosis or
nephrolithiasis on follow-up at 4.6 years of age with
normal renal function and urinary calcium excretion.
Figure 3 demonstrates the response to GH treatment.
After the first year of GH treatment on 4.9 mg/m2/week
(0.2 mg/kg/week), her height was 86.9cms (SDS −3.7),
with a height velocity of 6.5cms/year. Serum IGF-1 levels
increased from 52 μg/L (−1.9 SDS) to 154 μg/L (−0.2
SDS) during this period. The GH dose was increased to
6.23 mg/m2/week with a corresponding increase in IGF-
1 to 193 μg/L (0.45 SDS) with further increment of
doses (7.24 mg/m2/week or 0.33 mg/kg/week) in the
next eight months. Her height velocity was 7.2cms/year
at the end of second year of treatment with serum IGF-1
of 128 μg/L (−0.63 SDS). At 5.11 years, her weight is
14kgs and height is 98.9cms (SDS −3.18).
Conclusions
The case highlights the clinical characteristics in a
child with KCS Type 2 due to a novel FAM111A muta-
tion. Hypoparathyroidism was diagnosed in the neo-
natal period and near normocalcemia was achieved
with calcium and calcitriol supplements. Investigations
ruled out the more commonly encountered DiGeorge
syndrome and mutations in the less common PTH and
CASR genes affecting PTH secretion, and GCMB gene
related to parathyroid embryogenesis. Our proband did
not have genetic confirmation of her condition until
4 years of age. We considered the diagnosis of KCS
Type 2 based on her clinical and radiological features.
The neonatal skeletal survey was inconclusive; how-
ever, a survey repeated at 2 years of age raised the
Fig. 1 Figures 1a and 1b demonstrate the facial phenotype of the patient. Large head with persistent fontanels, telecanthus, small palpebral
fissures, small pinched upturned nose with elfin facies. Figure 1c demonstrates the significant growth restriction at 3 years and 2 months of age
Fig. 2 Figures 2a and 2b demonstrate the small hands and feet respectively with triangular dysplastic nails
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possibility of KCS with the evidence of medullary sten-
osis. She had additional features including macrocrania
with widely separated sutures, dysmorphic features,
normal intellect and developmental milestones. The
absence of intellectual impairment and microcephaly
excluded KCS Type 1 and Sanjad Sakati syndrome.
The genetic cause of KCS Type 2 was first reported by
Unger et al., and involves the “Family with sequence
similarity 111, member A00 (FAM111A) gene
(NM_001142519.1)” as reported in five patients with
KCS Type 2 and five patients with severe osteocranios-
tenosis (OCS) [4]. KCS type 2 and OCS were allelic
disorders of different severity with each having a close
genotype-phenotype correlation. The p.Arg569His
(R569H) mutation was consistently associated with the
KCS phenotype while another mutation, p.Ser342del,
was associated with the lethal phenotype of OCS. Japa-
nese researchers also identified the same mutation in-
dependently in another four patients and they
concluded that R569H is a hot spot mutation for KCS
Type 2 [15]. Our proband has a novel FAM111A muta-
tion (p. Ser541Tyr), which lies in the same peptidase
domain as the hot spot mutation. Within this domain,
the S541 residue, along with H385, and D439 forms
the putative catalytic triad of FAM111A [4]. As a con-
sequence, the mutation in our proband may impair the
catalytic activity of FAM111A. The identified cases
from the two above-mentioned series were de novo
mutations [4, 15]. However, the earliest description of
KCS described a mother-to-son transmission [16] and
Fig. 3 Figure 3 demonstrates the growth and the response of the patient to growth hormone (plotted on the CDC growth chart). Inset: Height
SDS following growth hormone therapy
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Fig. 4 Figure 4 shows the head circumference of the patient
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this has been further elaborated in a second case of
mother-to-daughter transmission of the same mutation
with both mother and child affected [17] consistent
with an autosomal dominant inheritance.
FAM111A has very low overall sequence identity to
known proteins; however, the second half of the protein
has homology to a family of peptidases (IPR009003). We
generated a 3D protein model of FAM111A (Fig. 5b and
c) using a known protease with the highest sequence
similarity to FAM111A (SWISS-MODEL template ID
4ic6.1) [18]. The S541 residue appears to lie closer to
the core of the protein, consistent with its predicted role
as part of the catalytic triad (Fig. 5b) whereas the R569
residue appears to be on the outer surface of the protein
(Fig. 5c), as previously reported by Unger and colleagues
[4]. Furthermore, our functional predictions of Ser541-
Tyr suggest that the variant may have very damaging ef-
fects, in contrast to the tolerated and benign predictions
made on Arg569His [9]. Taken together, the pathogen-
icity of the novel FAM111A mutation in our proband
may be different to the previously identified hot spot
mutation.
FAM111A is constitutively expressed in bone and
parathyroid gland and may have a role affecting intracel-
lular pathways regulating normal bone development,
height gain, and parathyroid gland development and/or
Fig. 5 Figure 5 shows the overnight growth hormone (GH) test. Blood sample is collected every 20 min for GH and the physiological surge in GH
is profiled. GH levels during waking hours are normally low. During sleep, there are usually several pulses of GH >20 mU/L (7.7 μg/L), usually
associated with slow wave sleep. A peak GH response <10 mU/L (3.9 μg/L) suggests GH deficiency; a response of 10–20 mU/L (3.9–7.7 μg/L) may
suggest partial GH deficiency; a response >20 mU/L (>7.7 μg/L) is regarded as normal.(1 mU/L × 0.385 = 1 μg/L)
Fig. 6 Figure 6a shows relatively poor ossification of skull vault, patent metopic suture, widely separated sagittal sutures on anteroposterior view
of X-ray Skull. Figure 6b shows tubulated long bones with reduced medullary space and cortical thickening on anteroposterior view X-ray Tibia
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regulation [4, 15]; although the precise mechanisms are
unknown. FAM111A demonstrates nuclear localization
and interacts with the C-terminal of SV40 large T anti-
gen to promote viral replication in a transfected human
osteosarcoma cell line (U2OS) [19]. Studies evaluating
chromatin during DNA replication have identified inter-
action between FAM111A and proliferating cell nuclear
antigen, a key part of the complex involved in
stabilization of DNA polymerases during replication [20,
21]. Depletion of FAM111A in U2OS cells resulted in
delayed entry into S-phase and DNA synthesis [19]. The
interaction of GH signalling with FAM111A function ei-
ther directly or indirectly in utero and postnatally is not
yet elucidated. This will be an important area of future
investigation.
Patients with FAM111A mutations have severe short
stature (−3 to −7 SDS) [4]. KCS has been identified as a
cause for short stature with dysmorphic features in the
absence of hypoparathyroidism [22]. Our proband did
not exhibit prenatal growth restriction and growth fal-
tered in the first year of life. This is similar to the other
reported cases and hence it suggests that FAM111A is
predominantly involved with postnatal growth [9]. The
slow growth in our proband was striking in the absence
of dietary issues, coeliac disease or any other chronic ill-
ness. The anaemia, although persistent, was mild and
hence unlikely to contribute to the severity of growth re-
striction observed in our patient. She was eligible for
GH therapy under the ‘Short stature and slow growth’
category in Australia [8]. We initiated GH therapy at
3 years and 3 months of age with the intention of im-
proving final height despite normal constitutive GH
levels. There has been one other report of the use of GH
(dose unspecified) in a female patient with KCS Type 2
in whom GH was commenced at 3.6 years for short stat-
ure [22, 23]. An initial response in growth velocity was
not sustained in the latter patient and therapy was chan-
ged over to IGF-1 therapy, which was subsequently dis-
continued due to severe headaches, poor compliance
and poor growth response. Reintroduction of GH treat-
ment improved her growth velocity. The height SDS im-
proved from −5.99 at baseline to −3.38 at 12 years and
1 month [22]. In our patient, there was reportedly good
compliance to treatment throughout therapy and the
height SDS improved from −3.86 to −3.18. During her
first year of treatment, the height velocity of 6.5cms/year,
was below −1 SDS on the Bakker’s curve [24]. The GH
dose of 4.5 mg/m2/week (0.17 mg/kg/week) is the stand-
ard dose used for commencement of GH therapy in
Australia; this is lower than that used in other countries
(0.3 mg/kg/week). There was an improvement in height
velocity in the second year of treatment as the GH dose
Fig. 7 Figure 7a shows the FAM111A protein and Figures 7b and c show the 3D model. a The FAM111A protein is made up of 611 amino acid
residues. Residues 329 to 492 and 529 to 603 are part of an InterPro domain named Peptidase S1, PA clan (IPR009003). Our novel variant
p.Ser541Tyr lies in the same domain as a previously identified genetic variant, p.Arg569His, which has been associated with KCS Type 2. b and c
SWISS-MODEL was used to generate a putative 3D model of FAM111A using the model template 4ic6.1, a protease that had the highest
sequence identity (23.79%) to FAM111A. Only the peptidase domain of FAM111A could be modelled. Residue Ser541 is shown in 5B and Arg569
in Figure 7c
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increased, although the response remained suboptimal
even after therapy increased to 0.3 mg/kg/week as dem-
onstrated in Fig. 3. It is not known if doses above
0.3 mg/kg/week would have been effective at improving
growth velocity, as she was not eligible for higher GH
doses at the time of her treatment under the Australian
Growth Hormone Programme funded by the Pharma-
ceutical Benefits Scheme.
Many children with genetic and syndromic conditions
are eligible for GH therapy under the category of ‘Short
stature and slow growth’ in Australia. This group forms
the largest category of patients treated with GH during
childhood. In an observational study (1990–2013) of the
Australian Growth Hormone Programme, rates of non-
compliance approached 50% and early cessation of GH
treatment was noted [24]. The expense of treatment [25]
and the unknown long-term effects increase the com-
plexity of management [26] of patients with short stat-
ure. Normal variation in height extends beyond the
growth hormone-insulin-like growth factor 1 (GH-IGF-
1) axis [27]. Short stature in KCS Type 2 is not due to
perturbation of the GH-IGF-1 axis and is likely to be as-
sociated with a skeletal defect that limits growth. Recent
advances in sequencing have enabled more rapid identi-
fication of the genetic etiology in children with short
stature and support newer diagnostic and therapeutic
paradigms centred on understanding the genetics of the
growth plate and skeletal development [27]. These may
enable better targeting of GH treatment in children with
short stature. Case reports such as these provide import-
ant information for families and raise the issue of the
prioritization and costs of genetic tests prior to GH ther-
apy for short stature.
Although limited to a single case, this report aims to
provide clinicians with information regarding growth re-
sponse of KCS Type 2 with GH therapy. We propose
that clinical case reports such as ours and collaboration
between clinicians to establish and support international
registries monitoring and reporting the outcome of GH
therapy in rare genetic conditions such as KCS would be
helpful in moving towards personalised medicine and
guiding clinical decisions about the use and doses of GH
in short stature.
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